A promising strategy for the design of COVID-19 therapeutic proteins is a fusion of the extracellular domain of ACE2, the human receptor for SARS-CoV-2, with the Fc region of human immunoglobulin, IgG1, by a linker separating the two domains [15]. Here, ACE2 is linked to COVID-19.